Recently, Toll Biotech announced the completion of A round of financing of more than 100 million yuan. This round of financing is to help Toll Biotech develop its own Class I new drugs for autoimmune diseases and build the company's R&D center.

Founded in 2020, Toll Biotech, based on the world's leading Toll-like receptor immune regulation technology, focuses on the research and development of innovative drugs for autoimmune diseases, provides innovative therapies for regulating human immune response, and solves the pain points of the global immune regulation drug market. Based on the accumulation of immune regulation mechanism research and immune regulation drug research in recent 20 years, the team has creatively discovered new immune regulation mechanisms and several world-first immune regulation small molecule drugs by using leading new drug R&D technologies and platforms and obtained exclusive patents for small molecule drugs, covering major drug R & D countries and regions in the world. Multiple pipelines have been formed and rapidly promoted in the drug research and development of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma.

Toll Biotech has established a core team with complementary specialties. Its backbone includes internationally renowned experts in the field of immune regulation, chief physician of Rheumatology and Immunology Department of Peking Union Medical College Hospital, experts with many years of preclinical and clinical experience, and many doctors who graduated from internationally renowned universities. The team will spare no effort to promote the clinical research of the company's research projects and continuously enrich the R&D pipeline, and is determined to overcome the worldwide problems such as low response rate, high price, and high side effects of autoimmune diseases, make up for the shortcomings and gaps of existing drugs, promote the high-quality growth of the drug market and solve real problems for patients, inject innovative vitality into the research of national class I new drugs.

Toll Biotech has recently built a new drug R&D platform in the medical center of the Life Science Park, which is expected to be completed and settled in April. Based on the perfect pharmaceutical R&D environment and resources of the Life Science Park, Toll Biotech will further strengthen its R&D strength and expand its R&D pipeline.